dynamin(redirected from Dynamin GTPase)
Angeze (UK), Chemydur (UK), Cibral (UK), Cibral XL (UK), Dynamin (UK), Dynamin XL (UK), Elantan (UK), Elantan LA (UK), Imazin XL (UK), Imdur (UK), Imo LA (UK), Isib (UK), ISMO (UK), Isodur (UK), Ketanodur (UK), Modisal (UK), Monigen (UK), Monigen XL (UK), Monit (UK), Monit LS (UK), Monoket (UK), Monomax (UK), Monomax SR (UK), Monomax XL (UK), Monomil (UK), Monosorb (UK), Trangina (UK), Trangina XL (UK), Xismox (UK), Zemon (UK), Zemon XL (UK)
Pharmacologic class: Nitrate
Therapeutic class: Antianginal
Pregnancy risk category C
Promotes peripheral vasodilation and reduces preload and afterload, decreasing myocardial oxygen consumption and increasing cardiac output. Also dilates coronary arteries, increasing blood flow and improving collateral circulation.
Capsules: 40 mg
Capsules (extended-release): 40 mg
Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg
Tablets (chewable): 5 mg, 10 mg
Tablets (extended-release): 20 mg, 40 mg
Tablets (sublingual): 2.5 mg, 5 mg, 10 mg
Tablets: 10 mg, 20 mg
Tablets (extended-release): 30 mg, 60 mg, 120 mg
⊘Indications and dosages
➣ Treatment and prophylaxis in situations likely to provoke acute angina pectoris
Adults: 2.5 to 5 mg S.L. May repeat dose q 5 to 10 minutes for a total of three doses in 15 to 30 minutes.
➣ Prophylaxis of angina pectoris
Adults: 5 to 40 mg P.O. (dinitrate conventional tablets) two to three times daily. Or 5 to 20 mg (mononitrate conventional tablets) b.i.d. Or 30 to 60 mg (mononitrate extended-release tablets) once daily. After several days, dosage may be increased to 120 mg (given as single 120-mg tablet or two 60-mg tablets) once daily. Rarely, 240 mg/day (mononitrate extended-release tablets) may be needed.
• Heart failure
• Hypersensitivity to drug
• Severe anemia
• Acute myocardial infarction
• Angle-closure glaucoma
• Concurrent sildenafil therapy
Use cautiously in:
• head trauma, volume depletion
• elderly patients
• pregnant or breastfeeding patients
• Give oral form 30 minutes before or 1 to 2 hours after a meal. Make sure patient swallows tablets or capsules whole.
• Have patient wet S.L. tablet with saliva before placing it under tongue. To avoid tingling sensation, have him place tablet in buccal pouch.
CNS: dizziness, headache, apprehension, asthenia, syncope
CV: orthostatic hypotension, tachycardia, paradoxical bradycardia, rebound hypertension
EENT: sublingual burning (with S.L. route)
GI: nausea, vomiting, dry mouth, abdominal pain
Drug-drug.Aspirin: increased isosorbide blood level and effects
Beta-adrenergic blockers, calcium channel blockers, phenothiazines: additive hypotension
Dihydroergotamine: antagonism of dihydroergotamine effects
Sildenafil: severe and potentially fatal hypotension
Drug-diagnostic tests.Cholesterol: decreased level
Methemoglobin, urine vanillylmandelic acid: increased levels
• Monitor ECG and vital signs closely, especially blood pressure.
☞ In suspected overdose, assess for signs and symptoms of increased intracranial pressure.
• Monitor arterial blood gas values and methemoglobin levels.
• Teach patient to take oral drug 30 minutes before or 1 to 2 hours after a meal.
• Inform patient that drug may cause headache. Advise him to treat headache as usual and not to alter drug schedule. If headache persists, tell him to contact prescriber.
• Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.